Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46331 | 0.83 | PDE3B (0.43) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL18226992 | 0.81 | CYP11B2 (0.39) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL21038061 | 0.81 | GPR55 (0.40) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL21038292 | 0.80 | GABRA5 (0.39) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL21038289 | 0.79 | CYP11B2 (0.40) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL15889724 | 0.78 | CYP11B2 (0.40) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL2816111 | 0.78 | LMNA (0.42) | CYP11B2CYP11B1HSD17B10PDE3BPDE3A | |
| SCHEMBL21038848 | 0.78 | CYP11B2 (0.37) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL15911681 | 0.77 | CYP11B1 (0.47) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 | |
| SCHEMBL2039105 | 0.75 | PDE3B (0.38) | CYP11B2CYP11B1PDE3BPDE3AGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013188856-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-8604050-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | CYP11B2 28/4885CYP11B1 44/4885HSD17B10 386/4885 |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | CYP11B2 223/4885CYP11B1 337/4885HSD17B10 3443/4885 |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | CYP11B2 223/4885CYP11B1 337/4885HSD17B10 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.